Autonomix Medical (NASDAQ:AMIX – Get Free Report) and AtriCure (NASDAQ:ATRC – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, dividends, valuation, profitability, institutional ownership, risk and analyst recommendations.
Profitability
This table compares Autonomix Medical and AtriCure’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Autonomix Medical | N/A | -542.11% | -236.92% |
| AtriCure | -8.70% | -8.12% | -6.21% |
Institutional & Insider Ownership
10.8% of Autonomix Medical shares are owned by institutional investors. Comparatively, 99.1% of AtriCure shares are owned by institutional investors. 32.4% of Autonomix Medical shares are owned by company insiders. Comparatively, 3.2% of AtriCure shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Autonomix Medical | 0 | 0 | 1 | 0 | 3.00 |
| AtriCure | 0 | 0 | 8 | 0 | 3.00 |
Autonomix Medical currently has a consensus target price of $28.00, indicating a potential upside of 791.72%. AtriCure has a consensus target price of $42.00, indicating a potential upside of 9.18%. Given Autonomix Medical’s higher probable upside, research analysts plainly believe Autonomix Medical is more favorable than AtriCure.
Valuation & Earnings
This table compares Autonomix Medical and AtriCure”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Autonomix Medical | N/A | N/A | -$15.43 million | ($16.07) | -0.20 |
| AtriCure | $399.24 million | 4.70 | -$30.44 million | ($0.83) | -46.35 |
Autonomix Medical has higher earnings, but lower revenue than AtriCure. AtriCure is trading at a lower price-to-earnings ratio than Autonomix Medical, indicating that it is currently the more affordable of the two stocks.
Summary
AtriCure beats Autonomix Medical on 6 of the 11 factors compared between the two stocks.
About Autonomix Medical
Autonomix Medical, Inc., a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.
About AtriCure
AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.
Receive News & Ratings for Autonomix Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autonomix Medical and related companies with MarketBeat.com's FREE daily email newsletter.
